Nature Communications · 2022 · 12 citations · 24 references
Veterinary MedicineImmunologyPediatricsImmunizationVaccine ImmunologyVaccinologyAdverse Events Following ImmunizationClinical Vaccine TrialsPediatric ImmunizationVaccinationVaccine EfficacyVaccine SafetyBooster Dose EffectivenessBooster Dose EfficacyHomologous Booster ImmunizationPediatric VaccinationPediatric Vaccine TrialsSystemic Adverse EffectsSystemic Adverse ReactionsVaccine Safety In Infants
Data on safety and immunity elicited by a third booster dose of inactivated COVID-19 vaccine in children and adolescents are scarce. Here we conducted a study based on a double-blind, randomised, placebo-controlled phase 2 clinical trial (NCT04551547) to assess the safety and immunogenicity of a third dose of CoronaVac. In this study, 384 participants in the vaccine group were assigned to two cohorts. One received the third dose at a 10-months interval (cohort 1) and the other one at a 12-months interval (cohort 2). The primary endpoint is safety and immunogenicity following a third dose of CoronaVac. The secondary endpoint is antibody persistence following the primary two-dose schedule. Severities of local and systemic adverse reactions reported within 28 days after dose 3 were mild and moderate in both cohorts. A third dose of CoronaVac increased GMTs to 681.0 (95%CI: 545.2-850.7) in cohort 1 and 745.2 (95%CI: 577.0-962.3) in cohort 2. Seropositivity rates against the prototype were 100% on day 28 after dose 3. Seropositivity rates against the Omicron variant were 90.6% (cohort 1) and 91.5% (cohort 2). A homologous booster dose of CoronaVac is safe and induces a significant neutralising antibody levels increase in children and adolescents.
24
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection
Jennifer M. Dan, José Mateus, Yu Kato et al. · Science · 2021 · 3K citations · Full text
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Yunlong Cao, Jing Wang, Fanchong Jian et al. · Nature · 2021 · 2.1K citations · Full text
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Raquel Viana, Sikhulile Moyo, Daniel G. Amoako et al. · Nature · 2022 · 1.9K citations · Full text
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Delphine Planas, Nell Saunders, Piet Maes et al. · Nature · 2021 · 1.6K citations · Full text